Opposition to the Affordable Care Act (ACA) may explain why two pairs of states had very different performance outcomes in the federally facilitated marketplace (FFM) during the first open enrollment period.
Opposition to the Affordable Care Act (ACA) may explain why two pairs of states had very different performance outcomes in the federally facilitated marketplace (FFM) during the first open enrollment period.
The new analysis from the Urban Insititute, with funding by the Robert Woods Johnson Foundation, compares enrollment rates between North Carolina and South Carolina, and Wisconsin and Ohio.
According to the report, demographics, uninsurance rates and FFM premiums did not appear to explain the differences.
The states were chosen because North Carolina and Wisconsin both had relatively high enrollment rates compared with other FFM states and states using state-based Marketplaces, while South Carolina and Ohio had rates below the average FFM.
In Ohio and Wisconsin, the decision to expand Medicaid appears to have had the most impact. When 80,000 people lost Medicaid coverage in 2014, this identifiable group was steered to alternate coverage. In Ohio, there was a lack of a centralized message, according to the report, and the state suffered from lack of a collective outreach and enrollment strategy.
READ: Insurers help states expand Medicaid; private options multiply
In North Carolina versus South Carolina, anti-ACA sentiment was significant in both states but was more consistent and intense in South Carolina, according to the report. In addition, North Carolina had a robust outreach/ enrollment effort. Brokers and agent were important partners, and the state also a centralized scheduling system and a statewide toll-free ACA assistance number.
South Carolina’s navigator grant, which was used to provide community-wide assistance, was awarded to an out-of-state vendor with few ties to the community, another aspect that might have hurt outreach.
Affordability, lack of understanding about uninsurance terms, verification issues, and tensions between brokers and navigators were all cited as ongoing challenges to enrollment.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
FDA Sets Date for Full Approval, Broader Indication for Elevidys
February 16th 2024The FDA has set a PDUFA date of June 21, 2024, to convert the accelerated approval to full approval and expand the labeling of the gene therapy Elevidys beyond the current use in children aged 4 and 5 with Duchenne muscular dystrophy.
Read More